Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Type 1 diabetes
HbA1c less than or equal to 11%
Body mass index (BMI) less than or equal to 40.0 kg/m2
You may not be if
Total daily insulin dosage more than 100 IU or U/day.
Current smoking or smoking within the last 6 months
Impaired hepatic or renal function
Cardiac problems
Uncontrolled hypertension
Current proliferative retinopathy or maculopathy requiring acute treatment
Clareo Health | Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
